NCT05368207已完成不适用
Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient (Pemb-HT)
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1
- 试验地点
- 2
- 主要终点
- Progression free survival
研究概览
简要总结
This is a study of pembrolizumab as consolidation therapy for a patient with small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
详细描述
It is an open-label single patient Clinical Trial to be conducted at Princess Margaret Cancer Centre for a patient with Small Cell Carcinoma of Ovary - Hypercalcemic Type (SCCOHT) who has rare and aggressive malignancy with no current consensus on treatment approach and surveillance.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient with small cell carcinoma of the ovary, hypercalcemic type (SCCOHT)
排除标准
- 未提供
研究组 & 干预措施
Pembrolizumab
Experimental
Pembrolizumab will be given as an intravenous infusion at 200 mg, every 6 weeks, for 6 cycles.
干预措施: Pembrolizumab (Drug)
结局指标
主要结局
Progression free survival
时间窗: 2 years
Determined by CT scans
次要结局
- overall performance status(2 years)
- Exploratory Endpoint(2 Years)
- Objective evidence of response to treatment(2 years)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
2 期
Pembrolizumab in Treating Participants With Recurrent Ovarian CancerRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaNCT03732950Jonsson Comprehensive Cancer Center5
撤回
1 期
Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic CancersSCCOHTOvarian Endometrioid AdenocarcinomaEndometrial CancerOvarian Clear Cell TumorNCT04611139HonorHealth Research Institute
已完成
2 期
Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)High-grade Serous Ovarian CarcinomaOvarian CarcinomaNCT05446870Merck Sharp & Dohme LLC160
招募中
2 期
Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHTSmall Cell Ovarian CarcinomaNCT04602377ARCAGY/ GINECO GROUP27
招募中
2 期
Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in ChinaHead and Neck Squamous Cell CarcinomaNCT04857164Yuankai Shi150